Table 2.

Prevalence of ACPA subtypes among 1033 women from the Nurses’ Health Study and Nurses’ Health Study II in a nested case-control study, at the time of blood draw [1989-90 (NHS) or 1996-99 (NHSII)]

ACPA subtype*	Pre-clinical RA Cases (n=255)	Matched Controls (n=778)	p value
Biglycan	12 (4.7%)	7 (0.9%)	<0.001
Clusterin	26 (10.2%)	13 (1.7%)	<0.001
Enolase	6 (2.4%)	4 (0.5%)	0.02
Fibrinogen	45 (17.7%)	34 (4.4%)	<0.001
Histone 2A	14 (5.5%)	11 (1.4%)	0.001
Histone 2B	22 (8.6%)	13 (1.7%)	<0.001
Vimentin	38 (14.9%)	16 (2.1%)	<0.001
≥1 ACPA	59 (23.1%)	59 (7.6%)	<0.001
≥2 ACPAs	40 (15.7%)	16 (2.1%)	<0.001

P values are from univariable conditional logistic regression models.

^*For each ACPA subtype, antibodies against the following number of epitopes were tested. Subjects testing positive for antibody against one or more epitope were considered positive for that ACPA subtype: biglycan (1), clusterin (2), enolase (1), fibrinogen (5), histone 2A (2), histone 2B (2), vimentin (2)